https://adisinsight.springer.com/drugsafety/803669428?error=cookies_not_supported&code=7fe4a823-20c2-4a52-9338-963d8624b72f
Tozinameran - AdisInsight
A 30-year-old woman developed subacute cutaneous lupus erythematosus (SCLE) following administration of tozinameran for immunisation against COVID-19.The woman
adisinsight
https://adisinsight.springer.com/drugsafety/803610918?error=cookies_not_supported&code=49e3f135-4394-4b25-a1e6-4f29349a567c
Tozinameran - AdisInsight
In a study assessing safety of vaccination in multiple sclerosis (MS) patients, conducted between January 2021 and 20 May 2021 consisting of 482 MS patients,
adisinsight
https://adisinsight.springer.com/drugsafety/803735667?error=cookies_not_supported&code=ac034cd2-2cbd-4c59-abbe-09a5c8b7381f
Tozinameran - AdisInsight
A 32-year-old woman developed recurrence of autoimmune hepatitis following administration of tozinameran for immunisation against COVID-19 [route, dosage, time
adisinsight
https://adisinsight.springer.com/drugsafety/803619698?error=cookies_not_supported&code=0f5d6f56-beef-4385-92aa-0b033db95370
Immunosuppressants/tozinameran - AdisInsight
A prospective observational study (RENAISSANCE), involving 2569 health care workers of ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy to evaluate
immunosuppressantsadisinsight
https://adisinsight.springer.com/drugsafety/803927003?error=cookies_not_supported&code=420f865d-4293-49e4-bea3-8db13708625a
Tozinameran/Elasomeran - AdisInsight
A report described women who received BNT162b2 (tozinameran) or mRNA-1273 (elasomeran) during pregnancy and experienced placental detection of SARS-CoV-2 spike
adisinsight
https://adisinsight.springer.com/drugsafety/803895400?error=cookies_not_supported&code=4d068c55-32cb-45d7-a2b4-3801229ea665
COVID-19-vaccine/Tozinameran - AdisInsight
In a retrospective chart review cohort study incolving 12 paediatric or young adult patients who received covid-19 vaccination conducted between March 2021 and
covidvaccineadisinsight
https://adisinsight.springer.com/drugsafety/803907047?error=cookies_not_supported&code=1eb913bc-3e4e-4289-b757-728e2520cbfc
Tozinameran - AdisInsight
A 37-year-old woman developed atypical haemolytic uraemic syndrome (aHUS) following vaccination with tozinameran [dosage, route and time to reaction onset not
adisinsight
https://adisinsight.springer.com/drugsafety/803751138?error=cookies_not_supported&code=37928ef3-c914-4886-b03c-7a2a01af125f
AZD-1222/tozinameran - AdisInsight
In a study involving 51 patients who experienced symptoms consistent with immediate allergic reactions to BNT162b2 vaccine and referred to Clinical Immunology
azdadisinsight
https://adisinsight.springer.com/drugsafety/803648043?error=cookies_not_supported&code=9bca55b4-23ae-44f7-bc10-c84c3883f80a
Elasomeran/tozinameran - AdisInsight
In a case report, a 56-year-old woman and 82 year-old woman were described, who developed thrombocytopenia or thrombocytopenic-purpura following vaccination
adisinsight
https://extranet.who.int/prequal/vaccines/who-recommendation-biontech-tozinameranus-fda-covid-19-mrna-vaccine-nucleoside-modified
WHO recommendation BioNtech Tozinameran/US FDA - COVID-19 mRNA vaccine (nucleoside modified) | WHO...
us fda
https://adisinsight.springer.com/drugsafety/803589909?error=cookies_not_supported&code=abdb1411-4a52-4c03-b4cd-d5264b6ad0cf
Tozinameran - AdisInsight
A 27-year-old woman developed cutaneous reaction, fever, fatigue and pain at the injection site following administration of tozinameran vaccine.The woman,
adisinsight
https://adisinsight.springer.com/drugsafety/803854873?error=cookies_not_supported&code=2a53393d-f0e0-4904-9b4b-5bfef36adce1
Tozinameran - AdisInsight
A 79-year-old man developed acantholytic dyskeratosis after taking tozinameran for COVID-19.The man presented with a 3-month history of a pruritic, unilateral
adisinsight
https://adisinsight.springer.com/drugsafety/803671016?error=cookies_not_supported&code=8f6ec2ad-b011-41ee-b758-e151ad9948a6
Elasomeran/tozinameran - AdisInsight
In a case report, 2 patients [69-year-old man and 34-year-old woman] were described, who developed severe immune thrombocytopenia following administration of
adisinsight
https://covid-vaccine.canada.ca/comirnaty-originalomicron-ba1/product-details
COMIRNATY ORIGINAL/OMICRON BA.1 (tozinameran / riltozinameran) | COVID-19 vaccines and treatments...
Information about COMIRNATY ORIGINAL/OMICRON BA.1 (tozinameran and riltozinameran) authorized by Health Canada as a Vaccine for COVID-19.
https://adisinsight.springer.com/drugsafety/803927574?error=cookies_not_supported&code=786d4295-dd43-463b-981d-d0a6e97de41c
Tozinameran - AdisInsight
One hundred two patients with severe obesity and 54 individuals without obesity [ages and sexes not stated] received two doses of BNT162b2 [route, dose and
adisinsight
https://adisinsight.springer.com/drugsafety/803871113?error=cookies_not_supported&code=750da0f4-5595-41d4-8fcc-c70f9f91535e
Tozinameran - AdisInsight
A 61-year-old woman developed worsening of atypical non-arteritic anterior ischaemic optic neuropathy (NA-AION) following vaccination with tozinameran [route
adisinsight
https://adisinsight.springer.com/drugsafety/803702782?error=cookies_not_supported&code=9f3d4225-68a9-4326-b125-8c41c433a0cc
Tozinameran - AdisInsight
In a study of 99 patients, who attended the infirmary in United Kingdom for supervised Covid-19 vaccination between March 2021 and December 2021, and four
adisinsight
https://adisinsight.springer.com/drugsafety/803874096?error=cookies_not_supported&code=594fb429-51a7-43df-ae3c-7dae1268c2c4
Tozinameran - AdisInsight
In a prospective, observational, cohort study, involving 232 patients with herpes zoster (HZ) from October 2021 to January 2023; a patient [age and sex not
adisinsight
https://adisinsight.springer.com/drugsafety/803656455?error=cookies_not_supported&code=aadc3143-0ca0-4052-8da0-6f4ef2dfddf2
Tozinameran - AdisInsight
A 41-year-old woman developed COVID toes-like syndrome following COVID-19 immunisation with tozinameran.The woman, who had a history of bipolar disorder treated
adisinsight
https://adisinsight.springer.com/drugsafety/803740819?error=cookies_not_supported&code=bb19cec7-a03b-4ea4-be92-8799846e6bd7
Tozinameran - AdisInsight
In a prospective, observational, single-center study, 429 patients were enrolled, who received vaccination with tozinameran between July 2021 and October 2021,
adisinsight
https://adisinsight.springer.com/drugsafety/803927949?error=cookies_not_supported&code=3f848b75-4338-41a8-afec-0f1972377a86
Tozinameran - AdisInsight
A 37-year-old woman developed palpitations, chest discomfort and dyspnoea within two hours of receiving tozinameran for COVID-19 vaccination. The woman, who had
adisinsight
https://adisinsight.springer.com/drugsafety/803695937?error=cookies_not_supported&code=46c1fb58-5d3e-42fe-ba3b-82cef870ccdc
Tozinameran - AdisInsight
In a case series, two 17-year-old male patients were described, who developed myocarditis following an administration of tozinameran against COVID-19 [route and
adisinsight
https://adisinsight.springer.com/drugsafety/803676063?error=cookies_not_supported&code=cd2df959-fbf1-4f4d-94f4-c96122142e09
Tozinameran - AdisInsight
A 37-year-old woman developed severe eczematous eruption following administration of COVID-19 vaccine tozinameran.The woman received her first dose of
adisinsight
https://adisinsight.springer.com/drugsafety/803717159?error=cookies_not_supported&code=5f1c13fb-82d6-466f-a952-03b696478bea
Tozinameran - AdisInsight
A 73 year-old man developed pulmonary eosinophilia following tozinameran vaccination for immunisation against COVID-19 *.The man presented with a 3 week history
adisinsight